Remove 2025 Remove FDA Remove HIV Treatment and Prevention Agents
article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

IDStewardship

AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.

article thumbnail

Procedure Shows Promise for Sustained Weight Loss After GLP-1 Therapy

Drug Topics

1,2 “There is an extraordinary unmet need in obesity treatment, which is the ability for patients to stop GLP-1 drugs without regaining weight. 1 “These early Revita data are better than I expected and suggest the potential to prevent the weight regain we see in practice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention

Pharmaceutical Technology

Robert Barrie July 2, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Yeztugo, injected twice a year, offers more convenient dosing than daily pills. The US Food and Drug Administration (FDA) approved Yeztugo last month , bringing a more convenient PrEP option for adults and adolescents at risk of HIV exposure.

article thumbnail

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.

article thumbnail

Gilead hit with FDA clinical hold for batch of HIV trials

Pharmaceutical Technology

Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gilead said it is “committed to working with regulatory authorities to resolve the issues underlying the clinical hold” Credit: Melnikov Dmitriy via Shutterstock. Gilead is considered the leading big pharma in HIV treatments.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics.

FDA 73
article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.